Product Reports Resources Pricing Login Book a demo
Investor profile

RA Capital Management

Venture Capital · Founded 2001 · Boston, United States

We are dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools

314 portfolio companies Venture Capital · $40B invested · 500 investments · Investor rank #71 · Last investment 7/2026
Portfolio companies 314 ↑ 64% 5y
Decacorns 8 ↑ 20% 5y
Thoroughbreds 28 ↑ 10% 5y
Estimated holdings

RA Capital Management’s biggest current holdings.

An estimate of RA Capital Management’s largest live positions — disclosed shareholding × Dealroom’s latest valuation — across 2 companies where RA Capital Management is a named shareholder, worth about $215M in estimated equity value.

#CompanyEst. stakeValuationEst. value
  1. 1 FreenomeHealth · Unicorn 8.5% $1.5B $128M
  2. 2 SomatusHealth · Unicorn 3.5% $2.5B $88M

Estimated value = RA Capital Management’s disclosed ownership % × Dealroom’s latest company valuation; direct named stakes only, exited positions excluded. Figures are indicative, not reported marks. See the underlying cap tables on Dealroom →

Exits

RA Capital Management’s biggest exits.

Portfolio companies that IPO’d or were acquired at $1B+, with the valuation recorded at exit and — for those still public — their value today. Exit events come from each company’s funding-round history; entry stage from RA Capital Management’s transaction record.

$1.8B IPO · 2015
Entered Series B+Now $38BHealth
$7.5B IPO · 2018
Entered Series B+Now $19BHealth
$373M IPO · 2015
Entered Series B+Now $17BHealth
$457M IPO · 2019
Entered Series B+Now $13BHealth
IPO · 2020
Now $12BHealth
IPO · 2004
Now $12BHealth
$391M IPO · 2018
Entered Series B+Now $10BHealth
$320M IPO · 2015
Entered Series B+Now $9.2BHealth
$9.1B IPO · 2026
Entered Series B+Now $9.1BEnergy
$809M IPO · 2023
Entered Series B+Now $9.1BHealth
$90M IPO · 2016
Entered Series B+Now $8.4BHealth
$398M IPO · 2015
Entered Series B+Now $8.3BHealth
Portfolio analysis

Where RA Capital Management’s portfolio is concentrated.

Distribution of portfolio companies by headquarters country, sector, entry stage and current growth stage. Across all 314 portfolio companies. "Stage entered" is the first priced round the investor joined, derived from the investor’s transaction history.

By countryCount
  1. USA276
  2. UK12
  3. Denmark6
  4. Canada5
  5. China5
  6. Germany4
  7. Switzerland4
  8. Israel3
  9. Belgium2
  10. Ireland2
  11. Italy2
  12. Netherlands2
By sectorCount
  1. Health303
  2. Energy12
  3. Food5
  4. Enterprise Software3
  5. Robotics3
  6. Sports2
  7. Transportation2
  8. Fintech1
  9. Hosting1
  10. Kids1
  11. Media1
  12. Real Estate1
By stage enteredCount
  1. Series B+198
  2. Series A78
  3. Seed17
By growth stageCount
  1. Late Growth248
  2. Breakout Stage68
  3. Early Growth11
  4. Mature1
Portfolio market map

Inside RA Capital Management’s portfolio.

The 60 highest-funded portfolio companies, of 314 tracked.

Moderna Therapeutics
Health · Decacorn
$19B
Nscale
Hosting · Decacorn
$15B
Johnson & Johnson Innovative Medicine
Health
X-energy
Energy · Unicorn
$9.1B
Intarcia Therapeutics
Health · Unicorn
$3.9B
Freenome
Health · Unicorn
$1.1B
Element Biosciences
Health · Unicorn
$1.4B
Parabilis Medicines
Health · Unicorn
$4.5B
Bicycle Therapeutics
Health
Obsidian Therapeutics
Health
$642M
Cerevel Therapeutics
Health · Unicorn
$6.9B
Nimbus Therapeutics
Health
$840M
Century Therapeutics
Health
$308M
General Fusion
Energy
$710M
Avidity Biosciences
Health · Decacorn
$12B
Cidara Therapeutics
Health · Unicorn
$9.2B
Metsera
Health · Unicorn
$4.9B
Solid Biosciences
Health
$476M
Somatus
Health · Unicorn
$2.5B
CellCentric
Health
$880M
Olema Oncology
Health
$530M
Invivyd
Health · Unicorn
$1.8B
Arvinas
Health
Crinetics Pharmaceuticals
Health · Decacorn
$10B
Synthego
Health
$800M
CORXEL Pharmaceuticals
Health · Unicorn
$1.1B
NuScale Power
Energy · Unicorn
$2.1B
Surrozen
Health
$141M
Galecto | Damora Therapeutics
Health · Unicorn
$1.9B
Ollin Biosciences
Health · Unicorn
$1.3B
Verdiva Bio
Health · Unicorn
$2.0B
NewAmsterdam Pharma
Health · Unicorn
$2.7B
Abcuro
Health
$800M
SAB Biotherapeutics
Health
$170M
COMPASS Pathways
Health · Unicorn
$1.1B
Artios Pharma
Health
$765M
Metagenomi
Health
Carmot Therapeutics
Health · Unicorn
$2.7B
Vividion Therapeutics
Health · Unicorn
$1.5B
Ventus Therapeutics
Health
$280M
Angitia Biopharmaceuticals
Health
$520M
Alentis Therapeutics
Health
$900M
Windward Bio
Health
$825M
Day One Biopharmaceuticals
Health · Unicorn
$1.8B
Verve Therapeutics
Health
$566M
Everest Medicines
Health
$812M
Terremoto Biosciences
Health
$875M
Be Bio
Health
$650M
Tyra Biosciences
Health · Unicorn
$1.6B
Dianthus Therapeutics
Health · Unicorn
$5.0B
Tango Therapeutics
Health · Unicorn
$4.1B
Hemab Therapeutics
Health · Unicorn
$2.0B
Capstan Therapeutics
Health · Unicorn
$2.1B
Pyxis Oncology
Health
$160M
Aktis Oncology
Health
$744M
AltruBio
Health
$900M
ViaCyte
Health
$320M
ADCendo
Health
$712M
CG Oncology
Health · Unicorn
$5.4B
Star Therapeutics
Health
$500M
Portfolio founders

Where RA Capital Management’s portfolio founders come from.

176 founders across the 100 highest-funded portfolio companies — by current location, university attended, and the companies they worked at before founding. Sourced from the founder records the API links to each portfolio company.

LocationCount
  1. United States134
  2. United Kingdom13
  3. Denmark10
  4. Switzerland5
  5. Australia3
  6. China2
  7. Netherlands2
  8. Canada1
  9. Chile1
  10. France1
UniversityCount
  1. Massachusetts Institute of Technology12
  2. Harvard University11
  3. Harvard Medical School7
  4. Stanford University7
  5. University of California, Berkeley7
  6. University of Copenhagen4
  7. Dartmouth College3
  8. ETH Zurich3
  9. Stanford University School of Medicine3
  10. The University of Chicago3
Previous companyCount
  1. Harvard Medical School6
  2. Dana-Farber Cancer Institute5
  3. Genentech5
  4. McKinsey & Company5
  5. Novartis5
  6. Roche5
  7. Broad Institute4
  8. Sanofi Aventis4
  9. Amblyotech3
  10. GSK3
Figures on this page are sourced live from the Dealroom next-gen API, joined with Dealroom’s cap-table dataset (estimated holdings) and the Power Law Investor Ranking. News in “Featured in” is drawn from Dealroom’s own coverage — the stories that name this investor, not only those it is the subject of. Market sentiment is omitted until the API exposes it.